U-Neuron Biomedical

U-Neuron Biomedical P/B

The P/B (Price-to-Book Ratio) of U-Neuron Biomedical (6973.TWO) as of Oct 28, 2026 is 1.90. In the previous year, P/B (Price-to-Book Ratio) was 3.13 — a change of -39.37% (lower).

P/B

1.90

YoY

-39.37%

Last updated:

P/B (Price-to-Book Ratio) of U-Neuron Biomedical is 2024 1.90 . P/B (Price-to-Book Ratio) of U-Neuron Biomedical was 2023 3.13 . It decreases by -39.37% lower compared to the previous year.

The U-Neuron Biomedical P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2021
7.87 TWD
Jan 1, 2022
9.42 TWD
Jan 1, 2023
3.13 TWD
Jan 1, 2024
1.90 TWD
The U-Neuron Biomedical P/B history
YEARP/BYoY
1.90-39.37%
3.13-66.81%
9.42+19.70%
7.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about U-Neuron Biomedical stock

P/B (Price-to-Book Ratio) of U-Neuron Biomedical is 1.90 in 2024.

P/B (Price-to-Book Ratio) of U-Neuron Biomedical changed from 3.13 to 1.90, representing a -39.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s U-Neuron Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — U-Neuron Biomedical

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — U-Neuron Biomedical